Skip to main content
TipRanks
Go Ultimate75% OFF

Adaptive Biotechnologies (ADPT) Stock Price & Analysis

1,093 Followers

ADPT Stock Chart & Stats

$29.04-$0.44(-1.49%)
At close: 4:00 PM EST
$25$27.5$30Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$28.39 - $29.78
52-Week Range
$12.00 - $32.21
Previous Close
$29.48
Volume
N/A
Average Volume (3M)
2.16M
Market Cap
$4.70B
Enterprise Value
$5.52B
Total Cash (Recent Filing)
$298.95M
Total Debt (Recent Filing)
$408.97M
Price to Earnings (P/E)
―
Beta
1.15
Next Earnings
Feb 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Pharma Adoption

Rapid clinical volume growth and a substantially larger pharma backlog indicate expanding use of Adaptive’s testing platform across care and drug development. This supports multi-quarter revenue visibility, strengthens customer relationships, and creates a durable base for continued adoption.

High Margins And Operating Leverage

High gross margins, improving sequencing economics, and higher MRD adjusted EBITDA show that volume growth is translating into operating leverage. Lab efficiencies and scale can support reinvestment in data, automation, and product expansion while improving the path toward sustainable profitability.

Strengthening Clinical Relevance

Explicit inclusion in updated clinical guidelines strengthens clonoSEQ’s role in treatment monitoring and shared decision-making for multiple myeloma. Guideline recognition can support clinician adoption, repeat testing, and reimbursement discussions over the coming quarters.

Bears Say

Elevated Leverage

Debt has risen sharply while equity has declined, leaving Adaptive with less financial flexibility than in prior years. The higher leverage burden increases the importance of continued operating improvement and could constrain investment or amplify pressure if losses persist.

Profitability Remains Inconsistent

Despite a profitable quarter, Adaptive remains structurally loss-making on a trailing basis and does not expect near-term GAAP profitability to persist. Continued operating losses can consume financial resources and delay the point at which growth converts into durable cash earnings.

Reimbursement And ASP Pressure

As physicians monitor patients more frequently, additional tests may fall outside Medicare’s episode structure and reduce realized pricing. This creates a durable reimbursement risk for a growing testing model, potentially limiting revenue per test even as clinical volumes expand.

Adaptive Biotechnologies News

ADPT FAQ

What was Adaptive Biotechnologies’s price range in the past 12 months?
Adaptive Biotechnologies lowest stock price was $12.00 and its highest was $32.21 in the past 12 months.
What is Adaptive Biotechnologies’s market cap?
Adaptive Biotechnologies’s market cap is $4.70B.
When is Adaptive Biotechnologies’s upcoming earnings report date?
Adaptive Biotechnologies’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 92 days.
How were Adaptive Biotechnologies’s earnings last quarter?
Adaptive Biotechnologies released its earnings results on Nov 04, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.091 by $0.111.
Is Adaptive Biotechnologies overvalued?
According to Wall Street analysts Adaptive Biotechnologies’s price is currently Undervalued.
Does Adaptive Biotechnologies pay dividends?
Adaptive Biotechnologies does not currently pay dividends.
What is Adaptive Biotechnologies’s EPS estimate?
Adaptive Biotechnologies’s EPS estimate is -0.04.
How many shares outstanding does Adaptive Biotechnologies have?
Adaptive Biotechnologies has 161,876,700 shares outstanding.
What happened to Adaptive Biotechnologies’s price movement after its last earnings report?
Adaptive Biotechnologies reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.091. Following the earnings report the stock price went up 0.449%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies?
Hedge funds hold Adaptive Biotechnologies shares: the largest hedge-fund position in Adaptive Biotechnologies is 70,141,580 shares, and hedge funds increased their holdings by 3.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology